Furthermore, a benefit/risk tool has been developed on the basis of current available evidence and guidelines to support primary care clinicians in selecting individuals who are most likely to benefit from GLP-1 RA therapies, in addition to indicating clinical situations where caution is needed
We are building a continuous data layer that connects therapy with real-world patient insights enabling better decisions for clinicians and more meaningful evidence for pharmaceutical partners, he further adds
Without effective and timely interventions, prediabetes, which is the pre-stage of overt diabetes, can result in diabetes
And so, for me it was like, "Oh, this is just this wonderful tool that's such a needle mover." [00:25:05] And I firmly believe and I'm getting confirmation from other clinicians on this as well, and this is pretty well known in the space of longevity medicine and doctors who are using this peptide for some time is that the dose really makes the poison
There's a ton of misinformation in this most recent interview with her, and is what prompted my interest in going through the interview with you guys and correcting the incorrect information
